SynthesisEpidemiology and infection2023
Prevalence and distribution of non-typhoidal
Synthesis in Epidemiology and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.EBioMedicine · 2025Trial
- Critical Roles of O-Acetylation Revealed by Synthetic Trisaccharide Antigens for a Broad-Spectrum Anti-Salmonella Vaccine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mapping High-Rate Clusters of Animal Contact-Related Human Salmonella enterica Single-State Outbreaks in the United States, 2009-2022: A Spatial Epidemiological Approach to Inform Public Health Surveillance.Zoonoses and public health · 2026Article
- Antimicrobial resistance and genomic characteristics of nontyphoidal Salmonella strains from diarrheal patients in Shandong, China.Gut pathogens · 2026Article
- Age-Specific Concentrations and Seroprevalence of Antibodies Against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) Across 3 Sites in Kenya.The Journal of infectious diseases · 2026Article
- Development of a GMMA-based candidate vaccine against invasive nontyphoidalFrontiers in immunology · 2026Article
- Application of mNGS in traceability investigation of foodborne disease outbreaks caused byFrontiers in microbiology · 2026Article
- Development of an 8-valentFrontiers in immunology · 2026Article
- Seven Years ofMicroorganisms · 2025Article
- Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.Vaccine · 2025Review
- Characterization and genome analysis of a novel lytic phage vB_ntSalS-cftriSP11 infecting Salmonella typhimurium.Molecular biology reports · 2025Article
- High Prevalence ofPathogens (Basel, Switzerland) · 2025Article
- GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevantFrontiers in immunology · 2025Article
- The rise of non-typhoidalFrontiers in microbiology · 2025Article
- The First-Ever Encounter withInfectious disease reports · 2024Article
- Identification ofMicroorganisms · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To inform coverage by potential vaccines, we aimed to systematically review evidence on the prevalence and distribution of non-typhoidal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.